SPL026 With or Without SSRIs in Participants With MDD
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The main aim of the study is to test the safety and tolerability of single doses of SPL026
(N,N-dimethyltryptamine [DMT] fumarate, a psychedelic tryptamine) in patients currently
taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the
SSRI is not fully relieving their depression.